Occam Places Ann Taylor as Board Member at Comanche Biopharma
Comanche is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Investors include GV, F-Prime, and Population Health Partners. The company has just appointed Ann Taylor to its Board of Directors.
Ann has an extraordinary record of achievement as a clinical development professional, with a distinguished career spanning Academia and Big Pharma. She most recently served as CMO of AstraZeneca and had previously spent a decade at Novartis leading portfolio management at NIBR, following two decades at Harvard and MassGen. She currently serves on the Boards of Terns Pharmaceuticals and Unlearn, a private company applying AI to clinical trials.
Ann has an MD from Harvard Medical School.
Related Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.